Warburg Pincus-backed Laurus Labs eyes $660 mn valuation in IPO

November 29, 2016 | Ankit Doshi

Hyderabad-based drugmaker Laurus Labs Ltd is seeking a valuation of as much as Rs 4,521 crore ($660 million) through an initial public offering that begins next month.

Strides Shasun to buy Swedish firm Moberg Pharma's paediatric brand

November 25, 2016 | Joseph Rai

Drugmaker Strides Shasun Ltd said on Friday it will buy Sweden-based Moberg Pharma's paediatric brand – PediaCare – for $5 million as the company aims to expand its consumer healthcare portfolio.

Aurobindo Pharma to buy select Teva assets in France

November 25, 2016 | Ranjani Raghavan

Drugmaker Aurobindo Pharma Ltd said on Friday its French unit Arrow Generiques SAS has signed a pact to acquire select commercial products in France from Israel-based Teva Pharmaceutical Industries Ltd.

Exclusive: Mankind Pharma reviews strategy; begins prep work for IPO

November 24, 2016 | Ranjani Raghavan

Capital International-backed Mankind Pharma Ltd, which had previously said it would not look at an initial public offering before 2020, is relooking at its plan and has started preliminary work to go public, a top company executive told VCCircle.

Cipla generates four-fold returns from Chase Pharma stake sale

November 23, 2016 | Joseph Rai

Drugmaker Cipla Ltd has sold its entire stake in the US-based Chase Pharmaceuticals to a unit of Allergan Plc, making handsome returns from its investment of a little more than two years.

Sun Pharma to acquire majority stake in Russia’s Biosintez

November 23, 2016 | Joseph Rai

Sun Pharmaceutical Industries Ltd said on Wednesday it has agreed to acquire an 85.1% stake in Russian drugmaker JSC Biosintez as part of its strategy to expand in emerging markets.

Demonetisation claims first casualty on stock markets as GreenSignal Bio scraps IPO

November 22, 2016 | Ankit Doshi

GreenSignal Bio Pharma Ltd on Tuesday withdrew its initial public offering after failing to garner sufficient bids from institutional investors, as it bore the brunt of stock-market volatility after the Indian government’s shock decision to ban high-value currency notes and Donald Trump’s surpris

GreenSignal Bio’s IPO finally sees some institutional investor interest

November 21, 2016 | Ankit Doshi

GreenSignal Bio Pharma Ltd saw some traction from institutional investors on its penultimate day after it cut the issue price band and stretched the time period of the initial public offering (IPO) twice.

GreenSignal Bio’s IPO struggling; search for institutional investors continues

November 18, 2016 | Ankit Doshi

Chennai-based GreenSignal Bio Pharma Ltd made no headway in finding institutional investors on Friday, which is crucial to see through its initial public offering (IPO) that was twice extended due to unfavourable market conditions.

Collateral damage: GreenSignal Bio’s IPO makes another attempt to sail through

November 17, 2016 | Ankit Doshi

GreenSignal Bio Pharma Ltd is trying to fend off the tag of being the first company to fail to see through its initial public offering (IPO) in almost two years.



Upcoming Events